These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 745011

  • 1. The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
    Knoll J.
    J Neural Transm; 1978; 43(3-4):177-98. PubMed ID: 745011
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB.
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [Abstract] [Full Text] [Related]

  • 3. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W, Riederer P, Youdim MB.
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract] [Full Text] [Related]

  • 4. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS, Fazzini E, Volkow ND.
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E, Tárczy M.
    Acta Neurol Scand Suppl; 1983 Aug; 95():117-22. PubMed ID: 6428143
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Deprenyl as prophylaxis against Parkinson's disease?
    Sonsalla PK, Golbe LI.
    Clin Neuropharmacol; 1988 Dec; 11(6):500-11. PubMed ID: 3148365
    [No Abstract] [Full Text] [Related]

  • 12. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA.
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [Abstract] [Full Text] [Related]

  • 13. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E, Tárczy M, Takáts A, Mogyorós I, Köves A, Katona G.
    J Neural Transm Suppl; 1983 Dec; 19():283-90. PubMed ID: 6421993
    [Abstract] [Full Text] [Related]

  • 14. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW, Langston JW.
    J Neural Transm Suppl; 1987 Dec; 25():69-79. PubMed ID: 3123606
    [Abstract] [Full Text] [Related]

  • 15. Deprenyl (selegiline): the history of its development and pharmacological action.
    Knoll J.
    Acta Neurol Scand Suppl; 1983 Dec; 95():57-80. PubMed ID: 6428148
    [Abstract] [Full Text] [Related]

  • 16. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J, Hajba A.
    Acta Neurol Scand Suppl; 1983 Dec; 95():127-33. PubMed ID: 6428145
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. R-(-)-deprenyl and parkinsonism.
    Yahr MD.
    J Neural Transm Suppl; 1987 Dec; 25():5-12. PubMed ID: 3123605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.